Session

IBD (Posters)

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020
PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS
ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

NEW DIAGNOSTIC CAPABILITIES FOR CROHN_S DISEASE: USE OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM
NEW DIAGNOSTIC CAPABILITIES FOR CROHN_S DISEASE: USE OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM

TREATMENT AND OUTCOME OF ULCERATIVE COLITIS DURING THE FIRST 10 YEARS AFTER DIAGNOSIS IN A PROSPECTIVELY FOLLOWED POPULATION-BASED COHORT
TREATMENT AND OUTCOME OF ULCERATIVE COLITIS DURING THE FIRST 10 YEARS AFTER DIAGNOSIS IN A PROSPECTIVELY FOLLOWED POPULATION-BASED COHORT

COMPLICATIONS AND ADVERSE EFFECTS RELATED TO SURGICAL AND MEDICAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVELY RECRUITED POPULATION-BASED COHORT
COMPLICATIONS AND ADVERSE EFFECTS RELATED TO SURGICAL AND MEDICAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVELY RECRUITED POPULATION-BASED COHORT

INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN INDIVIDUALS WITH HIV IN BOTH DANISH AND US COHORTS
INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN INDIVIDUALS WITH HIV IN BOTH DANISH AND US COHORTS

INFLIXIMAB RESPONSE IN INFLAMMATORY BOWEL DISEASES IS LINKED TO INTERACTION BETWEEN MUCOSAL MICROBIOTA COMPOSITION AND HOST GENE-EXPRESSION
INFLIXIMAB RESPONSE IN INFLAMMATORY BOWEL DISEASES IS LINKED TO INTERACTION BETWEEN MUCOSAL MICROBIOTA COMPOSITION AND HOST GENE-EXPRESSION

SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS
SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS

IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY
IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY

POST-OPERATIVE COURSE OF CROHN_S DISEASE AFTER ILEOCAECAL RESECTION: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY
POST-OPERATIVE COURSE OF CROHN_S DISEASE AFTER ILEOCAECAL RESECTION: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY

GASTROINTESTINAL TOXICITY DUE TO IMMUNE CHECKPOINT INHIBITORS: CLINIC EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL
GASTROINTESTINAL TOXICITY DUE TO IMMUNE CHECKPOINT INHIBITORS: CLINIC EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL

PREVALENCE AND PREDICTIVE FACTORS OF FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION
PREVALENCE AND PREDICTIVE FACTORS OF FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION

RISK FACTORS FOR POOR POSTOPERATIVE OUTCOME IN PATIENTS WITH CROHN'S DISEASE UNDERGOING ILEOCECAL RESECTION
RISK FACTORS FOR POOR POSTOPERATIVE OUTCOME IN PATIENTS WITH CROHN'S DISEASE UNDERGOING ILEOCECAL RESECTION

SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES
SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES

COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

INCREASED RELAPSE RATE AFTER DISCONTINUATION OF IMMUNOMODULATOR MONOTHERAPY BUT NOT AFTER WITHDRAWAL FROM COMBINATION REGIMEN IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
INCREASED RELAPSE RATE AFTER DISCONTINUATION OF IMMUNOMODULATOR MONOTHERAPY BUT NOT AFTER WITHDRAWAL FROM COMBINATION REGIMEN IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Item 101 - 120 / 558
1 2 3 4 5
6
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28